Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Drugs to Tweak RAAS Response No Help in Acute COVID-19, RCTs Show

Caitlin E. Cox

April 19, 2023

News Daily News

Prehospital Troponin Testing With EMS Input Could Save a Lot of Money

Michael O'Riordan

February 07, 2023

News Daily News

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

L.A. McKeown

February 02, 2023

News Daily News

Meta-analysis Affirms Colchicine’s Myriad CV Benefits

Caitlin E. Cox

April 12, 2021

News Opinion CV Team Dispatch

January 2021 News Roundup

L.A. McKeown

January 01, 2021

News Conference News ESC 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

Caitlin E. Cox

August 31, 2020

News Daily News

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

Michael O'Riordan

July 13, 2020

News Features

The Mystery of the Missing STEMIs During the COVID-19 Pandemic

Shelley Wood

April 02, 2020

News Conference News ACC 2020

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

Caitlin E. Cox

March 28, 2020

News Daily News

Who Should Head to the Cath Lab in the COVID-19 Pandemic?

Michael O'Riordan

March 26, 2020

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Daily News

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

Michael O'Riordan

April 27, 2017

News Daily News

The Ups and Downs of Statin Adherence Around Acute MI Hospitalization

Todd Neale

May 25, 2016

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Daily News

Apixaban Lowers Hospitalization Rate vs. Aspirin in A-fib Patients

Jason Kahn

August 05, 2013

News Conference News

ASCOT: Unexplained Long-Term Mortality Benefit Found with Atorvastatin

August 29, 2011

Advertisement

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Drugs to Tweak RAAS Response No Help in Acute COVID-19, RCTs Show

Prehospital Troponin Testing With EMS Input Could Save a Lot of Money

Sepsis Emerges as Powerful CVD Risk Factor in Large US Analysis

Meta-analysis Affirms Colchicine’s Myriad CV Benefits

January 2021 News Roundup

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

Heart, Kidneys, Brain, and More: COVID-19’s Wide-ranging Effects

The Mystery of the Missing STEMIs During the COVID-19 Pandemic

Colchicine Cost-effective in Canada, and Even in the US: COLCOT

Who Should Head to the Cath Lab in the COVID-19 Pandemic?

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Thirty-Day Readmission in Acute MI Not Linked With Hospital Care or Clinical Outcomes

The Ups and Downs of Statin Adherence Around Acute MI Hospitalization

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

Apixaban Lowers Hospitalization Rate vs. Aspirin in A-fib Patients

ASCOT: Unexplained Long-Term Mortality Benefit Found with Atorvastatin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content